CleveMed Blogs

Parkinson’s disease (PD) is a neurodegenerative disorder that is caused by the death of dopamine producing neurons in the brain. Primary motor symptoms of PD include tremor, rigidity, bradykinesia (slowed movements or hesitations) and gait and balance issues. Since there is currently no cure for PD, the symptoms are treated typically with pharmaceutical interventions.

One of the more common medications prescribed for PD is L-Dopa, which is used to increase levels of dopamine in the brain. While effective, a common issue with the use of L-Dopa is that there is a fine line between the correct amount of medication and too much. Too much medication results in dyskinesias, or wild, uncontrollable movements. Also, the effectiveness of L-Dopa decreases over time.

When L-Dopa is no longer effective as a treatment for PD symptoms, patients can consider a surgical procedure called deep brain stimulation, or DBS. When patients opt to have DBS surgery, tiny electrodes are implanted in the brain through a hole in the skull which emit pulses of stimulation that aide in symptom alleviation. The location of the electrode can vary depending on the patient but the two most common are subthalamic nucleus (STN) and the globus pallidus interna (GPi). A patient can also have electrodes implanted on one side of the brain or both, depending on whether their symptoms are unilateral or bilateral. The electrode or electrodes connect to a pulse generator which is typically implanted below the skin near the collarbone. The implanted pulse generator, or IPG, controls the electrode stimulation output. Parameters such as amplitude (the power of the stimulation), frequency (how often the stimulations pulses occur) and duration (how long each pulse lasts) must be set.

During DBS surgery the patient is awake and fully aware. This is because a nurse must perform motor assessments with the patient to determine if the electrode has been placed in an optimum location and depth. This assessment includes motor tasks that the patient is asked to complete to determine the severity levels of their symptoms. This can sometimes be time consuming as the patient must complete the assessment each time the electrode is moved.

Once surgery is completed, patients will return to the clinic to have the IPG settings adjusted. Again, a nurse will administer a motor assessment and alter the amplitude, frequency and duration of the pulses until an optimum combination is found with best alleviates the patient’s symptoms. This adjustment is repeated a number of times as symptoms worsen due to the progression of the disease.

While the exact reason DBS works is still not known, the number of PD patient lives the surgery has improved is dramatic. Patients with debilitating motor symptoms that leave them nearly incapable of performing activities of daily living can have the ability to move and function as they did before their diagnosis of PD. This is not to say that DBS does not have risks. It is a major surgical operation and results are not the same for each patient. The first step to determining whether or not DBS would be appropriate for any PD patient would be to discuss their options with a certified movement disorder clinician or neurologist.

To demonstrate the benefits of Kinesia, a compact patient worn device for assessing Parkinson’s disease (PD) motor symptom severity, and the tremor scoring feature recently released, CleveMed has launched the new interactive website UPDRS.CleveMed.com.

Parkinson’s disease motor symptoms are typically assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS), a subjective rating scale in which clinicians visually assess patient tremor symptoms and assign a 0 to 4 score based on severity. UPDRS.CleveMed.com highlights some of the reliability and consistency issues of the current method of PD patient evaluation.

The CleveMed UPDRS Scoring Challenge is an online educational tool intended for movement disorder clinicians and researchers, patients, caregivers or anyone interested in Parkinson’s disease motor symptom evaluations. The interactive site allows a visitor to view and rate a series of videos displaying Parkinson’s disease patients performing tasks for evaluating tremor. After each short video is complete, the user enters the score they feel is appropriate ranging from 0 to 4, 0 being the absence of symptoms and 4 being the most severe, and the next video starts. Once the twelve videos are scored, the user scores are compared to scores from two movement disorder specialists for the same videos. This demonstrates the variability in scores that can occur between different clinicians for the same patient, which is an issue with the subjective UPDRS. Scores are also compared to the automated scoring provided by Kinesia which demonstrates the benefits of having a device that can provide consistent, repeatable results.

Everyone is encouraged to try the site out and see how you would perform again actual clinicians when rating tremor symptom severity. If you find it interesting, please pass it along to others who may feel the same. Any comments, suggestions or questions on the site are welcome at any time.

Kinesia is a system for objectively monitoring and tracking the severity of Parkinson’s disease symptoms in conjunction with clinician evaluations using the Unified Parkinson’s Disease Rating Scale (UPDRS). The device uses tiny motion sensors (accelerometers and gyroscopes) to collect patient symptom data and, using a Bluetooth radio, wirelessly transmits that information to a PC. An addition to the system has just been released which includes automated tremor scoring based on the 0-4 scoring method of the UPDRS. Before Kinesia, there was no objective way to consistently track symptoms, making this a large advance in the way Parkinson’s disease patients are monitored.

The Kinesia patient unit is worn on the hand and wrist while patients follow video instruction for completing upper extremity motor tasks. After the completion of the tasks, algorithms in the software automatically score three tremor tasks for evaluating rest, postural and kinetic tremor on a 0-4 scale based on the UPDRS. In addition to the scoring being automated and repeatable, the scores are provided with better resolution than the whole numbers given with the UPDRS. Kinesia will assign scores such as 1.29, 3.75 or 0.84 to provide clinicians with a more exact picture of a patient’s symptoms. Reports can be generated and tremor symptom history can be viewed by their clinician, assisting them in making decisions regarding the progression of the disease, the patient’s current medication or other methods of treatment. A peer reviewed publication documenting clinical utility was accepted by The Movement Disorders Journal and is currently available online at http://www3.interscience.wiley.com/journal/121634261/abstract

There are many other symptoms that affect PD patients outside of tremor, including bradykinesia (slowed movements or hesitations), rigidity, gait and balance issues and dyskinesias (wild, involuntary movements caused by an overabundance of dopamine in the brain – the result of a patient being overmedicated). Automated tremor scoring is only the beginning of the development of Kinesia . Researchers at CleveMed are in the process of conducting a large clinical trial involving three movement disorders centers and one hundred fifty PD patients. The data collected during this study will aid in the development of algorithms for automated scoring of bradykinesia and dyskinesias. The overall goal is to include scoring for a large majority of the motor symptoms that affect PD patients.

Kinesia is a compact patient worn device that was developed to measure and assess the severity of the motor symptoms associated with Parkinson’s, including tremor and bradykinesia. For more information on Parkinson’s, click here. Currently, symptoms are assessed using a subjective rating system called the Unified Parkinson’s Disease Rating Scale, or UPDRS. During a typical exam, patients are instructed to perform a series of motor tasks for evaluating symptoms. While the tasks are completed, a clinician watches and visually assess the symptoms, assigning a 0-4 score based on the severity with 0 being the absence of symptoms and 4 being the most severe.

Because of the subjective nature of the UPDRS, there is definitely room for error. Studies have shown that clinicians can score the same symptom severity differently on different days and different clinician scores can vary for the same severity level. Also, patient’s symptoms can vary greatly throughout the course of a day and a one time clinical visit can not capture these fluctuations. It is important to have a method that objectively and consistently tracks patient’s symptoms at the clinic and at home.

Better tracking of symptoms can be incredibly helpful for Parkinson’s patients. Medication is usually the first method of treating symptoms and there is a fine line between under-medicating a patient which can cause symptoms to still persist, prescribing just the right amount and over-medicating a patient which causes a patient to become dyskinetic, or to have wild involuntary movements.

Kinesia is a device that is worn on the hand of the patient while they complete tasks for assessing tremor and bradykinesia. The device then, using algorithms built into the software, automatically assigns a 0-4 score for the tasks. Kinesia provides a consistent repeatable method for evaluating and scoring symptoms and more objectively track the progression of the disease. The device can also be sent home with a patient and the tasks completed at regular intervals to monitor the fluctuation of the patient’s symptoms. Tracking these fluctuations with Kinesia could assist a clinician in regulating medication time and dosage, leading to increased time without symptoms and less of a risk of under or over medicating.

The latest version of Kinesia was just released in January, so check back regularly for updates on the device being used in the field, current clinical trials and new uses for Kinesia. Ultimately, the hope is to assist in creating an improved quality of life for Parkinson’s patients in the US and around the world.